Conversion to sirolimus for chronic renal allograft dysfunction: Risk factors for graft loss and severe side effects

Nephrology Dialysis Transplantation

Volumn 23, Issue 11, 2008, Pages 3727-3729

  Abramowicz, Daniel ^a   Hadaya, Karine ^a   Hazzan, Marc ^b   Broeders, Nilufer ^a   Hoang, Anh Dung ^a   Ghisdal, Lidia ^a   Noel, Christian ^b   Wissing, Karl Martin ^a  

^a ERASME HOSPITAL   (Belgium)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Graft survival; Proteinuria; Renal transplantation; Sirolimus; Toxicity

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CREATININE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID;

ABDOMINAL ABSCESS; ABSCESS; ACNE; ACUTE PANCREATITIS; ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LOADING DRUG DOSE; MALE; PERITRANSPLANT ABSCESS; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEINURIA; RENAL GRAFT DYSFUNCTION; RETROSPECTIVE STUDY; RISK FACTOR; STROKE; SURVIVAL RATE; WOUND HEALING IMPAIRMENT;

EID: 54149120306     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn332     Document Type: Article

References (16)

1. Dominguez J, Mahalati K, Kiberd B et al. Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. Transplantation 2000; 70: 1244
2. Diekmann F, Waiser J, Fritsche L et al. Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity. Transplant Proc 2001; 33: 3234
3. Cotterell AH, Fisher RA, King AL et al. Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent. Clin Transplant 2002; 16: 49
4. Morelon E, Kreis H. Sirolimus therapy without calcineurin inhibitors: Necker hospital 8-year experience. Transplant Proc 2003; 35: 52S
5. Fairbanks KD, Eustace JA, Fine D et al. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl 2003; 9: 1079
6. Egidi MF, Cowan PA, Naseer A et al. Conversion to sirolimus in solid organ transplantation: a single-center experience. Transplant Proc 2003; 35: 131S.
7. Diekmann F, Budde K, Oppenheimer F et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004; 4: 1869
8. Bumbea V, Kamar N, Ribes D et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005; 20: 2517
9. Stallone G, Infante B, Schena A et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005; 16: 3755
10. Groth CG, Backman L, Morales JM et al. Sirolimus European Renal Transplant Study Group. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999; 67: 1036
11. Kreis H, Cisterne JM, Land W et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252
12. Diekmann F, Gutierrez-Dalmau A, Torregrosa JV et al. Sirolimus monotherapy: feasible immunosuppression for long-term follow-up of kidney transplantation - a pilot experience. Transplantation 2005; 80: 1344
13. Mulay AV, Cockfield S, Stryker R et al. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation 2006; 82: 1153
14. Schena FP, Wali RK, Pascoe MD et al. A randomized, open label, comparative evaluation of the safety and efficacy of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients [Abstract]. Transpl Int 2005; 18(Suppl 1): 155
15. Diekmann F, Campistol JM. Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks. Nephrol Dial Transplant 2006; 21: 562
16. Wali RK, Mohanlal V, Ramos E et al. Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction. Am J Transplant 2007; 7: 1572